Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 1—January 2003

Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 2

Comparison of pharmacokinetic and pharmacodynamic parameters for four fluoroquinolones and selected bacterial speciesa

Streptococcus pneumoniae Pseudomonas aeruginosa
Fluoroquinolone
Dose
(mg)
Cmaxa,b
(mg/L)
AUC24b
(mg x h/L)
MICc
Cmax:MIC
AUIC
MICc
Cmax:MIC
AUIC
Ciprofloxacin
500
3.0
28
2
1.5
14
4
0.75
7

750
3.6
32
2
1.8
16
4
0.9
8
Levofloxacin
500
5.7
48
1
5.7
48
16
0.36
3
Moxifloxacin
400
4.5
48
0.25
18
192
8
0.56
6
Gatifloxacin 400 4.2 34 0.5 8.4 68 8 0.52 4.25

aCmax, peak serum concentration of the drug; AUC, area under the curve; MIC, minimal inhibitory concentration; AUIC, ratio of the AUC to MIC.
bReferences 4144.
cReference 16.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO